The need for analytical technology that reveals the effect of production process on CQAs of viral particles in gene therapy and vaccines, and the most common analyses requested.
Our MiniTEM system is now part of Testa Center’s (GE Healthcare subsidiary) analytical toolkit
We at Vironova are delighted to have entered into a collaboration with Testa Center in Uppsala, Sweden! Testa Center is a GE Healthcare subsidiary (GE owns 100%) and a separate business entity running as non-profit and with legal autonomy.
Actionable insight to see and secure the quality of your viral particles at different steps of your process
In Gene Therapy, viral vector stability and integrity must be carefully investigated before scaling up production. Specific process steps can be evaluated to understand what impact they have on viral particle integrity. Viral particle...
How to walk the talk - Vironova and Hitachi in smart research and business collaboration
An example of how Hitachi High Technologies and Vironova AB walk the talk in TEM research and business collaboration. To achieve great advancement by relying and leveraging on each others core competencies and competitive edge, with sustainable,...
Vironova won the Finals Hitachi´s Transformation Awards in Las Vegas.
We did it! Today Team Vironova won the People's Choice Finals in Hitachi´s Transformation Awards in Las Vegas.
Webinar: How Artificial Intelligence Can Address Analytical Challenges in Gene Therapies and Vaccines
Accurate and reliable analytics are crucial in the development and manufacturing of viral-based drugs. In this webcast key concepts and strategies will be discussed how to apply analytical information to the development of these emerging therapies.
Direct vs. indirect methods for characterization and analysis of subvisible particles – A comparative study
Characterization and analysis of subvisible particles of biological origin can be challenging or give insufficient information. In this study Adeno associated virus (AAV) particles contaminated by host cell proteasomes are analysed with direct...
Annual General Meeting 2019
The Annual General Meeting of Vironova AB will be held on Monday 24 June 2019 at 15.00, at the Company's premises, at Gävleatan 22, in Stockholm - Sweden.
Putting Viral Clearance Capabilities to the Test - Vironova Biosafety
Best practices from Vironova Biosafety. Vironova Biosafety specialize in viral clearance studies for biological drugs. These kinds of drug products based on live cells have an inherent risk for viral contamination that could cause serious harm or...